E
Exelixis, Inc.
EXEL · Healthcare
Q4 FY2025
Earning ended Jan 2, 2026Report generated Mar 10, 2026
One Drug, One Bet, One Clock Running Down
The market is treating Exelixis as a melting ice cube trading on terminal multiple math, but the combination of structurally unbreachable gross economics, a compounding buyback, and a next-generation asset with a genuine clinical signal means the actual risk-reward is asymmetric in a way the current price doesn't reflect — the bear case is already priced in, and the bull case is free.
Flowly Score
Apr 16 Close
+317%$44.38
Fair Value
$185.00
69
Strongat $44.38
Business Strength7/10
Cabozantinib's multi-kinase fingerprint has earned genuine guideline entrenchment and switching costs across six indications — that's a real moat. The single-molecule concentration and the unresolved franchise handoff to zanzalintinib are what keep this from scoring higher.
Financial Resilience8/10
Operating cash flow consistently exceeds reported net income, gross margins are structurally near-perfect, and the balance sheet carries more cash than debt — this business funds itself and then some. The FCF explosion over the past two years isn't a one-year gift; it's the harvest phase of a decade of fixed-cost investment.
Growth & Trajectory6/10
The top-line is maturing — high single-digit revenue growth on the core drug — but zanzalintinib's FDA acceptance and seven ongoing pivotal trials create a credible second act that the market isn't yet awarding full credit for. The NET approval demonstrating over a hundred million in new revenue within a single year shows the indication-expansion playbook still has working capital.
Valuation8/10at $42.37
A mid-teens P/E and low-teens EV/EBITDA on a business printing near-best-in-class gross margins and an FCF yield north of seven percent is the kind of compression that typically reflects either structural fear or market neglect — and the structural fear here looks overcalibrated given the pipeline optionality sitting entirely off the multiple. Even the pessimistic DCF scenario implies meaningful upside from today's price.
Risk4/10
Single-molecule concentration is existential, not merely uncomfortable — if an IO bispecific or cabo-nivo successor displaces first-line RCC dominance before zanzalintinib proves itself, the core thesis unravels simultaneously from two directions. The binary nature of the Phase 3 pipeline readouts means a bad clinical quarter could reprice this business violently.
The investment case rests on a simple tension: the market is awarding cabozantinib a multiple that implies near-certain obsolescence, but the underlying cash machine is performing at elite levels right now — high gross margins, accelerating free cash flow, a shrinking share count, and a balance sheet with net cash. That combination — quality asset at distressed-asset pricing — is the entry point. The P/E contraction from the mid-thirties to the mid-teens over three years hasn't tracked any deterioration in business quality; it's tracked narrative fatigue around single-drug concentration. Where this business is heading depends entirely on two clinical readouts: zanzalintinib in third-line colorectal cancer and the RCC Phase 3. The colorectal cancer approval, if it lands, opens an indication that is meaningfully larger by patient volume than kidney cancer, and the 2025 GI sales force expansion suggests management is treating the launch as operationally real, not speculative. The NET business crossing nine figures in revenue within a year of approval proves the indication-expansion model still works — each new label is essentially costless incremental revenue flowing through an already-built commercial infrastructure. The single biggest concrete risk is bispecific antibody displacement in first-line RCC. If a clean Phase 3 head-to-head emerges showing that a PD-1/VEGF bispecific — several of which are in late-stage trials — matches or beats cabo-nivo without the TKI toxicity profile, the flagship indication loses its defended position precisely when the franchise handoff to zanzalintinib is still unproven. That sequence — core indication pressure plus pipeline uncertainty simultaneously — is the scenario where the current multiple proves generous rather than punitive.